Abstract 35P
Background
Chemotherapy-induced alopecia is one of the most distressing symptoms for cancer patients undergoing cytotoxic chemotherapy. In this prospective two-center study, the objectives were to determine the efficacy and toxicity of a scalp-cooling device in the prevention of alopecia associated with chemotherapy.
Methods
Breast cancer patients who were planning for (neo)adjuvant chemotherapy consisting of taxane- and/or anthracycline- based regimens, with or without anti-HER2 therapy were invited to participate. They underwent a scalp cooling system offered by the Orbis Paxman Hair Loss Prevention System. The following were measured during the study: extent of hair loss based on Dean score (score ranges 0-4; 0-2 score reflects hair loss of 50% or less) 4 weeks after the completion of all cycles of chemotherapy, as determined by patients and independent assessors. Adverse events (AEs), specifically alopecia and potential study-related AEs, were graded according to NCI CTCAE v4.0.
Results
52 patients were enrolled into the study. 6 patients were excluded due to subjects’ own request (3), abnormal thyroid function (2) and anaemia (1). Of the remaining 46 patients, 50% each had taxane-based and taxane-anthracycline-based regimens. 3 of the 46 patients did not undergo any assessments after enrolment, resulting in 43 being assessable for outcomes. The median age was 51.5 years. A Dean score of 0-2 for hair loss was reported by 30.2% of the patients and 32.6% of the assessors. Only 4 patients (8.7%) did not require wearing headcover during the study. Alopecia grading were: grade 0 (9.3%), grade 1 (23.3%) and grade 2 (67.4%). Potential study-related AEs included dizziness [grade 1 (11.6%); grade 2 (2.3%)], headaches [grade 1 (4.7%)], complaint of cooling [grade 1 92.3%)]; there were no grade 3 or above toxicities.
Conclusions
In contrast to previous reports, the current scalp cooling system provided a lower efficacy in preventing alopecia in breast cancer patients also undergoing chemotherapy.
Acknowledgement: The scalp cooling system was provided by Orbis Paxman Hair Loss Prevention System.
Clinical trial identification
NCT4630080.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract